

Regional approaches for supporting UHC medicines strategies

Country Perspective



**Escalante, Dr Socorro
WHO Viet Nam**



Viet Nam: Medicines Profile



Source: All data are of 2011,
www.gso.gov.vn unless otherwise
indicated

Photo Credit: WHO Country Office for
Viet Nam

Total Market Value: U\$ 2.4 billion

Local production share: 46%

Availability: 30%

Expenditure:

- 1.7% of the GDP
- 22.5 US\$ per capita
- 42% of the total health expenditure [3]
- 60-70% of the total health insurance expenditure in 2009-2011 [4]
- 41% of the total cost for in-patients [5]
- 79% of the total cost for out-patients [6]


Prices:

- IB : 0.42 -41.76 x IRP
- LPG: 0.09 – 5.14 x IRP

Escalante, Dr Socorro
WHO Viet Nam



Access to Medicines Framework for UHC



Who are the stakeholders?

- Government: regulation, access
- Industry: trade, innovation, access (?)
- Providers: profit, access (?)
- Patients: affordability, equitable access

Can we bring them altogether to improve access under the context of UHC?



Country Approaches

The Medicines Transparency Alliance (MeTA)

- Multi-stakeholder
- Built around issues of transparency, accountability and good governance
- Focus on transparency of information, but also improving access to essential medicines



Country Approaches

The Medicines Transparency Alliance (MeTA)

- MeTA in Viet Nam?
- Technical Working Group (TWG) on pharmaceuticals under the Health Partnership Group (HPG): on its inception



Country Approaches

1. Medicines management and policies:
 - WHO-led: Aide Memoire on Strategic Collaboration in Improving Access to Medicines, signed by WHO and MOH in 2010
 - WHO-UNIDO-MOH Collaboration on the policy of local pharmaceutical production
 - WHO-UN on access and MDG's
 - Government side: DAV-led



Country Approaches

2. Information for decision making:

Key players:

WHO, MOH, Health Strategy and Policy Institute (HSPI), Universities, VSS, Technical Programmes

Products

- Assessment of the NMP and the Pharmaceutical Law
- Specific medicines on TB, MCH, ARV's
- Review of the reimbursement list
- Expenditure and consumption monitoring
- Rational use of medicines monitoring
- Quality monitoring
- Industry scan



Country Approaches

3. Technical Issues

- Local pharmaceutical production: WHO-UNIDO, MOH and Viet Nam National Pharmaceutical Companies Association (VNPCA)
- Medicines Pricing: WHO, MOH, MoF
- Patent and trade issues: WHO, UNAIDS, UNCTAD
- Rational Use: WHO, Karolinska Institute, French Embassy, MOH, VSS



Country Approaches

3. Technical Issues

- Quality Monitoring: WHO, USG-USP; National Institute of Drug Quality Control (NIDQC)
- Counterfeit monitoring: WHO, UNODC, French Embassy
- Pharmacovigilance: WHO, WHO-UMC, MSH, National PV-Centre, National PV Centre in New Zealand



Country Approaches

Participation in regional collaborations and harmonization

- ASEAN Harmonization
- ASEAN Technical Working Group in Pharmaceuticals
- Price-monitoring: Piemed
- SSFFC: Pilot country of WHO's global monitoring program
- Pharmacovigilance: WHO-UMC
- Mekong Country Medicines Monitoring: French Embassy
- Mekong countries programmes on UHC
- Fellowships, study exchanges around the region



Essential Medicines: The forgotten MDG
Framework for Viet Nam



Thank you

Escalante, Dr Socorro
WHO Viet Nam

